FDA Approves First D1/D5 Dopamine Agonist for Parkinson’s Disease in Decades

The U.S. Food and Drug Administration approved a groundbreaking drug for Parkinson’s disease over the weekend, marking the first dopaminergic breakthrough in decades. Tavapadon, developed by pharmaceutical company AbbVie, will be sold under the brand name Juvmo as a once-daily pill for adults living with the progressive neurological disorder. The approval introduces a fundamentally different approach to treating a disease that affects more than 11 million people worldwide, according to AbbVie.

Since the 1960s, Parkinson’s treatment has revolved around one critical substance: dopamine. In people with the disease, brain cells that produce dopamine gradually die, and without it movement becomes slow, stiff and tremulous while balance deteriorates. Most existing Parkinson’s drugs attempt to compensate for that loss, each employing a different mechanism to restore the brain’s chemical balance.

Dopamine functions like a key that binds to receptors on nerve cells-much like locks-and activates them. The neurotransmitter has five receptor types divided into two families, and they participate in nearly everything dopamine controls in the body, including movement, sleep, appetite, mood, attention and thinking. Each receptor family concentrates in different brain regions, which means a drug aimed at one family behaves distinctly from one targeting the other.

How Traditional Parkinson’s Medications Work

The primary drug used to treat Parkinson’s disease, levodopa, contains a substance that the body converts into dopamine. Alongside it are drugs that mimic dopamine and bind directly to its receptors, known as dopamine agonists, including pramipexole and ropinirole. These medications act mainly on D2 receptors, but those receptors also populate brain regions associated with reward, thinking and the body’s automatic regulation.

That dual action helps explain some troublesome side effects these drugs can cause, including compulsive behaviors, sudden sleep attacks and swelling in the legs. For people living with Parkinson’s disease, maintaining consistent control of motor symptoms becomes increasingly challenging as the disease progresses. Oral levodopa remains the foundation of treatment and often proves effective at controlling symptoms, but many patients require higher and more frequent doses over time.

These dosage adjustments can help restore symptom control yet may also contribute to treatment-related complications such as dyskinesia-involuntary movements that develop as a side effect. About 70% of people living with Parkinson’s disease have their oral levodopa dose increased within the first year of therapy, highlighting the urgent need for alternative treatment approaches.

Tavapadon’s Novel Mechanism Targets Different Receptors

Tavapadon represents a dopamine agonist as well, but it targets fundamentally different receptors: D1 and D5. D1 receptors concentrate mainly in brain circuits that drive voluntary movement, making them an attractive therapeutic target. For decades, researchers have attempted to develop a drug that would selectively activate them, but early efforts encountered significant obstacles.

Initial compounds showed that the concept could work, but they broke down too quickly in the body, absorbed poorly when taken as pills and caused severe involuntary movements. One experimental drug also caused a dangerous drop in blood pressure, forcing researchers back to the drawing board to engineer a more stable and effective molecule.

Tavapadon was specifically designed to overcome those historical problems. It resists the enzymes that break down dopamine and remains in the body for an extended period, allowing it to be administered once daily. Crucially, it does not fully activate the receptor but only partially stimulates it, a characteristic that may contribute to its more favorable side effect profile compared to earlier attempts.

Clinical Trial Results Support FDA Approval

“The approval of JUVMO marks the first dopaminergic breakthrough for Parkinson’s disease in decades,” said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie.

The FDA’s approval received support from the Phase 3 TEMPO clinical program, which demonstrated significant improvements in daily functioning, increased “on” time without troublesome dyskinesia and a favorable safety profile. The drug can be taken once daily with or without levodopa therapy, offering patients flexibility across the Parkinson’s disease continuum.

After 85 weeks on tavapadon, 93% of clinical trial participants had not increased their oral levodopa dose, and 94% of participants with early Parkinson’s disease had not started oral levodopa. These figures suggest the drug may help delay or reduce dependence on escalating doses of traditional medications.

Understanding Parkinson’s Disease and Dopamine Loss

Parkinson’s disease is a progressive neurological disorder in which dopamine-producing nerve cells in a brain region called the substantia nigra disappear gradually. Dopamine proves essential for controlling movement, and as its levels fall, people develop characteristic symptoms like tremor, stiffness, slowness of movement and problems with balance.

This fundamental mechanism explains why many Parkinson’s treatments focus on increasing dopamine levels or mimicking its effects in the brain. Traditional approaches have centered on either supplying the brain with dopamine precursors or activating dopamine receptors directly, but until now, therapeutic options have remained limited in their receptor selectivity.

New Treatment Reduces Difficult Tradeoffs

“People living with Parkinson’s and the clinicians who care for them have long faced difficult tradeoffs between motor control, treatment burden and tolerability. Clinicians now have a new treatment option that targets dopamine pathways differently and reduces the difficult tradeoffs associated with D2/D3 selective dopamine agonists,” said Thakkar.

The distinction between tavapadon and currently available dopamine agonists lies in its selective targeting of D1/D5 receptors rather than D2/D3 receptors. Researchers have investigated whether this selectivity can provide motor symptom relief while avoiding some adverse effects linked with broader dopamine receptor activation. The approval represents a meaningful addition to the treatment landscape for a disease that demands better therapeutic options as it progresses.

Tavapadon’s approval offers hope that more targeted approaches to dopamine receptor activation may open new avenues for managing Parkinson’s disease symptoms while minimizing the treatment complications that have challenged patients and clinicians for decades.